Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen
Biochemistry article published in Seminars in Thrombosis and Hemostasis (2001)
Abstract
Platelets tether to collagen in both a von Willebrand factor (vWF)-dependent and a vWF-independent manner. We have recently characterized a recombinant protein, saratin, isolated from the saliva of the leech Hirudo medicinalis, expressed it in Hansenula polymorpha, and studied its effect on direct and indirect platelet-collagen interactions. Saratin dose dependently inhibited the binding of purified human vWF to human type I and III collagens (IC(50)= 0.23 +/- 0.004 and 0.81 +/- 0.04 microg mL(-1), respectively) and to calf skin collagen (IC(50)= 0.44 +/- 0.008 microg mL(-1)). Furthermore, saratin showed a similar inhibitory potency against the binding of human, rodent, and porcine plasma vWF to these collagens. In a flow chamber under conditions of elevated shear (2700 s(-1)), saratin dose dependently and potently inhibited platelet aggregate formation on a collagen-coated surface (IC(50)= 0.96 +/- 0.25 microg mL(-1)), but at reduced shear (1300 s(-1)) a rightward shift in the dose-response curve was noted (IC(50)= 5.2 +/- 1.4 microg mL(-1)). Surface plasmon resonance analysis revealed both high and low affinity binding sites for saratin on human collagen type III (K(d) 5 x 10(-8) M and 2 x 10(-6) M, respectively). Although low concentrations of saratin, which inhibited platelet adhesion under increased shear (i.e., saturation of high-affinity binding sites), had no effect on vWF-independent collagen-induced platelet aggregation, high concentrations (i.e., saturation of low-affinity binding sites) were found to inhibit platelet aggregation. These data demonstrate that saratin is a potent inhibitor of vWF-dependent platelet adhesion to collagen and hence may have therapeutic potential as an antithrombotic agent.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Recombinant saratin, produced in Hansenula polymorpha from Hirudo medicinalis saliva, dose-dependently inhibited von Willebrand factor binding to type I and III collagens and, under elevated shear, potently inhibited platelet aggregate formation on collagen, suggesting potential as an antithrombotic agent.
Why This Matters for Hirudotherapy
This work characterized recombinant saratin, a protein from Hirudo medicinalis salivary secretion expressed in Hansenula polymorpha, examining its inhibition of von Willebrand factor (vWF)-dependent and vWF-independent platelet-collagen interactions. Saratin dose-dependently blocked purified human and plasma vWF binding to type I/III collagens and potently inhibited platelet aggregate formation on collagen under elevated shear, with surface plasmon resonance revealing high- and low-affinity collagen binding sites. The study delineates a defined leech-secretome molecule with mechanistic antithrombotic activity at the platelet-collagen interface. The data are biochemical/flow-chamber in vitro findings (using human, rodent, and porcine plasma), not clinical results, and the abstract's therapeutic-potential claim is inferential rather than demonstrated in patients.
Citation
Reference (Vancouver style)
Barnes CS, Krafft B, Frech M, Hofmann UR, Papendieck A, Dahlems U, et al. Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen. Semin Thromb Hemost. 2001;27(4):337-348. doi:10.1055/s-2001-16887. PMID: 11547356
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 26, 2026 · Site last updated: November 1, 2026